Shashank Joshi/LinkedIn
Feb 2, 2026, 16:45
Shashank Joshi: Switching Among Oral Anticoagulants
Shashank Joshi, Senior Consultant at Joshi Clinic and President of Indian Academy of Diabetes, shared post on LinkedIn:
“Switching among oral anticoagulants
Switching from a DOAC to warfarin
- Apixaban
If continuous anticoagulation is needed, discontinue apixaban and start a parenteral anticoagulant with warfarin; continue the parenteral agent until the INR is therapeutic on warfarin (PI). Note that apixaban can contribute to INR elevation.
-or-
Overlap warfarin with apixaban until the INR is therapeutic on warfarin, testing right before the next apixaban dose to minimize the effect of apixaban on INR elevation (ASH). - Rivaroxaban
Discontinue rivaroxaban and start a parenteral anticoagulant with warfarin; continue the parenteral agent until the INR is therapeutic on warfarin (PI). Note that rivaroxaban can contribute to INR elevation.
-or-
Overlap warfarin with rivaroxaban until the INR is therapeutic on warfarin, testing right before the next rivaroxaban dose to minimize the effect of rivaroxaban on INR elevation (ASH).
Switching from warfarin to a DOAC
- Rivaroxaban
Stop warfarin, monitor the PT/INR, and start rivaroxaban when the INR is less than 3 (PI). - Apixaban
Stop warfarin, monitor the PT/INR, and start apixaban when the INR is less than 2 (PI).
Switching from one DOAC to a different DOAC
- Any DOAC
Start the second DOAC when the next dose of the first DOAC would have been due; do not overlap.”

Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Mar 26, 2026, 17:03Tilden Sokoloff: PRP Injections Enhance Sexual Function in Premenopausal Women
-
Mar 26, 2026, 17:02Mahesan Subramaniam: Japan Brings Mitochondrial Therapy to the Frontline of Cardiology
-
Mar 26, 2026, 17:01Kanishk Kumar: Discovering The Newest Advances in Hypercholesterolemia Research
-
Mar 26, 2026, 17:00Ifeanyichukwu Ifechidere: Breaking the INR Myth in Liver Disease
-
Mar 26, 2026, 16:57Georgiana Toma: Why Nutrition is a Hematologist’s Secret Weapon
-
Mar 26, 2026, 16:56Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?
-
Mar 26, 2026, 16:39Faizan Khan: Cold Agglutinins and Their Effects on CBC Results
-
Mar 26, 2026, 16:38Strengthening Research and Partnerships at THSNA 2026 – NBDF
-
Mar 26, 2026, 16:38Gareth Owens: Advancing Patient Engagement in Cardiothoracic Surgery